Autologous CIK cells in combination with ICIs (pembrolizumab) [128], inflammatory cytokines (IL-2) [128], and TKIs (sorafenib) [129] have exhibited synergistic effects on RCC tumors in the clinic. The gene discussed is IL2; the disease is renal cell carcinoma.